Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
MedPage Today on MSN20h
NCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown ContinuesThe American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
AstraZeneca Pharma India has received approval from CDSCO to import and distribute the cancer treatment drug Durvalumab ...
Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...
With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
Stocks like India Pesticides, HFCL, NDR Auto Components, JSW Steel, GR Infraprojects, Biocon, Oil and Natural Gas Corporation ...
AstraZeneca Pharma India gets CDSCO nod for durvalumab to treat LS-SCLC: Our Bureau, Bengaluru Monday, March 10, 2025, 15:30 Hrs [IST] AstraZeneca Pharma India, received a Central ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback